Tegafur and Temozolomide

Phase 2Small molecule

Tegafur and Temozolomide is one of 118 small molecule programs targeting Pancreatic Neuroendocrine Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Neuroendocrine TumorActive, not recruiting

Breast CancerActive, not recruiting

Gastric CancerActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Pancreatic Neuroendocrine TumorPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tegafur and Temozolomide

CChinese Academy of Medical Sciences

Phase 2

1 2

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 3

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 5

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 6

Tianeptine

Pfizer

Preclinical

1 7

Lipegfilgrastim

Merck & Co.

Preclinical

1 8

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

1 9

Leronlimab

CCytoDyn, Inc.

Preclinical

1 10

Systemic Treatment

TTaproot Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01492543·30 enrolled

Gastric Cancer1 trial

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

Active, not recruiting·YYu jiren·Phase 2·NCT04515615·52 enrolled

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03204019·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Tegafur and Temozolomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tegafur and Temozolomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tegafur and Temozolomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChinese Academy of Medical Sciences

Tegafur and Temozolomide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Gastric Cancer1 trial

Metastatic Head and Neck Cancer1 trial

Squamous Cell Carcinoma1 trial

Pancreatic Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News